Navigation Links
Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
Date:10/11/2010

MANHATTAN BEACH, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced that President and CEO Robert Brooke will present a company overview during Precision IR's Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference.  The webcast presentation will be available Wednesday, October 13, at 1:00 p.m. Eastern time (10:00 a.m. Pacific time) by visiting the company's website at www.genesis-biopharma.com and an archive of the presentation will be available for 90 days.  

"We look forward to our presentation at the Informed Investors Conference as an opportunity to broaden our investment-community exposure during a pivotal period in our development," said Robert Brooke, President and CEO of Genesis Biopharma.  "Following the recent completion of a $700,000 financing, we are well positioned to advance development of our promising anti-CD55 antibody program."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies.  For more information on the company, visit www.genesis-biopharma.com.

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential,, "suggests," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Announces $700K Private Financing
2. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
3. American Medical Systems and Tissue Genesis Sign $1.1 Million Collaboration Deal
4. Organogenesis CEO Geoff MacKay and COO / CFO Gary Gillheeney Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winners in New England
5. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
6. Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009
7. Dr. Damien Bates of Organogenesis Speaks on Regenerative Medicine for Opening Night of TEDMED Conference
8. ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
9. ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
10. ValGenesis, Inc., the Leading Provider of Validation Lifecycle Management Solutions to Regulated Life Science Companies, Today Announced Support for EMC Documentum v.6.5
11. ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):